Can Drusen Go Away? Managing Drusen for Eye Health

Drusen can and do go away on their own, but their disappearance is not necessarily reassuring. In the eye, drusen regression often signals damage to the underlying tissue rather than healing, and in many cases it marks the transition from an intermediate stage of age-related macular degeneration (AMD) to a more advanced, vision-threatening one. About 15% of eyes with macular drusen show a substantial decrease in drusen volume over time, and the eyes that lose the most drusen tend to be the ones that had the most to begin with.¹ Understanding what drusen regression actually means, and what you can do to slow drusen growth in the first place, matters far more than hoping they simply vanish.

What Drusen Actually Are

Drusen are yellowish deposits that accumulate beneath the retina, specifically between the retinal pigment epithelium (RPE) and a thin membrane called Bruch’s membrane. They are made up of proteins, lipids, and cellular waste products. Proteomic analyses have identified more than 100 distinct proteins in drusen, including proteins involved in inflammation, immune defense, and cholesterol transport.² Some of these proteins, like complement factors and amyloid components, overlap with the deposits found in atherosclerosis and other inflammatory diseases.³ Small, hard drusen are extremely common as people age and generally considered benign. Larger, softer drusen are the ones linked to AMD progression and the ones that raise clinical concern.

Not All Drusen Behave the Same Way

Ophthalmologists distinguish between several types of drusen, and the type matters a great deal when thinking about whether they can regress and what that regression means.

Soft drusen, sometimes called basal linear deposits, sit beneath the RPE. They have a well-characterized lifecycle: they grow, the RPE can migrate on top of them, and eventually they may collapse, often leaving behind areas of RPE loss and tissue atrophy.⁴ This collapse is a form of regression, but it is the kind that leads to geographic atrophy, a slow, irreversible loss of central vision.

Subretinal drusenoid deposits (SDDs), also called pseudodrusen or reticular pseudodrusen, sit in a different location: above the RPE, in the space between the RPE and the photoreceptors. They contain some of the same proteins as conventional drusen but differ in their lipid makeup.⁵ SDDs are dynamic structures that can grow, merge with each other, or regress over time.⁶ They are strong independent risk factors for late AMD. When SDDs regress, the result is often outer retinal atrophy, a form of late AMD that has only recently been recognized as distinct from classic geographic atrophy.⁵

There are also optic disc drusen, which are calcified deposits buried within the optic nerve head. These are a completely different entity from macular drusen. While both involve calcified extracellular material, their composition differs quantitatively and they arise for different reasons.⁷ If your doctor mentions drusen and you are unsure which type they mean, it is worth asking, because the prognosis and management differ considerably.

Why Disappearing Drusen Can Be Bad News

This is the counterintuitive heart of the issue. In many chronic conditions, seeing deposits shrink would be encouraging. With macular drusen, the opposite is often true. The formation of large, confluent drusen and accompanying pigment changes appear to be among the first insults in atrophic AMD. When those drusen are subsequently reabsorbed and the RPE beneath them is lost, the result is geographic atrophy, the advanced dry form of AMD that accounts for roughly 85 to 90% of AMD cases.⁸

Refractile drusen, which have a glistening appearance on clinical exam, illustrate this process clearly. They appear to represent a late stage of drusen regression, and their presence is associated with RPE loss and the development of geographic atrophy.⁹ So rather than being a sign of recovery, refractile drusen are more like evidence that the drusen have collapsed and taken the supporting tissue with them.

That said, drusen regression is not always catastrophic. Occasional case reports document drusen disappearance in unusual circumstances, such as after surgical repair of a retinal detachment, with improved vision afterward.¹⁰ These are isolated observations, though, and it remains unclear whether the mechanism behind this kind of regression is fundamentally different from the destructive regression seen in AMD progression. The take-home message: drusen shrinking on an imaging scan should prompt close follow-up rather than celebration.

How Drusen Affect Your Vision Day to Day

Many people with small or moderate drusen notice no symptoms at all. Vision loss from drusen tends to be subtle and gradual. But research using microperimetry, a test that maps the retina’s sensitivity point by point, shows that drusen volume is significantly linked to reduced retinal sensitivity even before obvious vision loss sets in.¹¹ Each additional unit of drusen volume corresponds to a measurable dip in sensitivity at that spot on the retina.¹²

People with subretinal drusenoid deposits tend to notice functional changes earlier and more acutely than people with conventional drusen. Slow dark adaptation, where your eyes take unusually long to adjust after going from a bright room to a dark one, and poor contrast sensitivity are particularly associated with SDDs.⁵ Testing with dim light conditions (scotopic testing) and specific color stimuli can reveal these deficits in areas directly overlying the drusen.¹³ If you have been told you have drusen and you are struggling with night driving or reading in dim light, this is a real and measurable phenomenon, not just your imagination.

Can Treatment Shrink Drusen?

No treatment currently approved for AMD is designed specifically to reduce drusen. But several approaches have been tested, and the results so far are mixed and instructive.

High-Dose Statins

A small study tested high-dose atorvastatin (the drug in Lipitor, at 80 mg daily) in patients with large soft drusen. Of 23 patients who completed at least a year of follow-up, about ten showed drusen regression with a modest gain in visual acuity, and none progressed to the advanced wet (neovascular) form of AMD during the study.¹⁴ This result attracted attention, but it comes from a single small, uncontrolled study. The drusen regression seen here could be the healthy kind or the destructive kind, and without a control group, it is hard to know how much credit to give the drug versus the natural fluctuation of drusen over time. Larger, randomized trials are needed before high-dose statins could be recommended specifically for drusen management.

Laser Treatment

Subthreshold nanosecond laser therapy was tested as a potential way to slow progression in intermediate AMD. The concept was to use very brief, low-energy laser pulses to stimulate the RPE without causing visible damage. A randomized trial (the LEAD study) evaluated this approach and found no significant difference between the laser-treated group and the control group in drusen volume, visual function measures, or progression to late AMD.¹⁵ Earlier, less rigorous studies had shown some promise, but the randomized trial essentially closed the door on this approach as a standalone treatment.¹⁶

Complement Inhibitors

Because complement proteins, part of the immune system’s inflammatory cascade, are abundant in drusen and genetically linked to AMD risk, there has been intense interest in drugs that block complement activity. At least 14 different complement inhibitors have been tested across nearly 40 clinical trials.¹⁷ One early trial using eculizumab, a systemic complement blocker, found no significant reduction in drusen volume.¹⁸

More recently, two complement inhibitors have been authorized in the United States specifically for geographic atrophy, the advanced dry AMD stage. They show moderate ability to slow the growth of atrophic lesions, but they have not demonstrated improvements in visual function.¹⁹ These drugs are not prescribed to shrink drusen in the intermediate stage. Their target is the geographic atrophy that can follow drusen regression, so they represent a treatment for the aftermath rather than the deposits themselves.

Diet, Supplements, and Lifestyle

The most practical tools for managing drusen right now are not drugs but dietary and lifestyle choices. The evidence here is not about making drusen disappear. It is about slowing their growth and reducing the risk that intermediate AMD progresses to the vision-stealing late stages.

The AREDS2 trial remains the landmark study. It tested supplements containing lutein, zeaxanthin, and omega-3 fatty acids in people who already had intermediate or advanced AMD in one eye. In the primary analysis, lutein plus zeaxanthin did not reach statistical significance for reducing progression to advanced AMD overall.²⁰ However, an exploratory comparison within the trial found that participants who took lutein and zeaxanthin as a replacement for beta-carotene (in the original AREDS formula) had about an 18% lower risk of progressing to late AMD compared to those taking the old formula with beta-carotene.²¹ This swap also eliminated the increased lung cancer risk that beta-carotene posed for smokers, which is why current AREDS-based supplements use lutein and zeaxanthin instead.

Beyond targeted supplements, broader dietary patterns matter. A Mediterranean-style diet, rich in fruits, vegetables, fish, nuts, and olive oil, has been associated with slower drusen growth. In one analysis drawn from the AREDS study population, the highest adherence to a Mediterranean diet was linked to about a 21% lower risk of progressing to large drusen compared to the lowest adherence.²² A systematic review of Mediterranean diet studies found broadly consistent results, with about a 17% reduced risk of drusen size progression among higher-adherence groups.²³

Smoking is the single most modifiable risk factor for AMD progression. Animal research shows that cigarette smoke exposure induces the same structural changes beneath the retina that characterize early AMD: thickening of Bruch’s membrane, formation of basal deposits, and damage to the RPE.²⁴ If you smoke and have been told you have drusen, quitting is the single highest-impact change you can make. The drusen may not shrink, but the risk of progression to advanced AMD drops substantially.

The Role of Genetics in Drusen Progression

Your genes influence not just whether you develop drusen but how quickly they grow and how likely they are to progress. Variants in complement pathway genes (particularly CFH and C3) and in the ARMS2/HTRA1 region are among the strongest genetic predictors of drusen size progression.²⁵ In the eculizumab trial mentioned above, drusen growth was actually dependent on how many complement risk alleles a patient carried, even though the drug itself did not significantly reduce drusen volume.¹⁸

This genetic component explains why some people with drusen never progress beyond the intermediate stage while others advance to geographic atrophy or wet AMD relatively quickly, and why two people with the same dietary habits and similar drusen loads can have very different outcomes. Genetic testing for AMD risk alleles is commercially available, though it is not yet standard practice in most clinics. Knowing your genetic risk profile could, in principle, help tailor how aggressively you and your doctor monitor your eyes, even if it does not yet change the available treatments.

The intersection of genetics and diet is worth noting. The same study that identified genetic risk alleles for drusen progression also found that diet quality was an independent factor. Having a poor diet on top of high genetic risk compounds the problem, while good dietary habits can partially offset genetic vulnerability. This is genuinely encouraging for people who feel that their genetic makeup leaves them helpless.

Monitoring and Imaging

If you have drusen, your ophthalmologist is almost certainly tracking them with optical coherence tomography (OCT), a non-invasive imaging technique that produces cross-sectional images of the retina in exquisite detail. OCT can measure drusen volume, detect the structural risk signs that precede progression (like pigment changes and disruptions to the photoreceptor layers), and distinguish conventional drusen from subretinal drusenoid deposits.²⁶ Retinal imaging captured over serial visits is what allows doctors to track whether drusen are growing, stable, or regressing, and to watch for the signs that regression is causing tissue damage rather than representing improvement.

Artificial intelligence is beginning to play a role in this monitoring. Machine-learning models trained on OCT scans can predict drusen regression and progression events with reasonable accuracy, using features like average druse thickness and maximum druse height.²⁷ These tools are not replacing ophthalmologists, but they may eventually help flag the patients who need more frequent visits or who are candidates for emerging treatments as they become available. The practical upshot for patients right now is straightforward: if you have intermediate AMD, keeping your scheduled imaging appointments is one of the most important things you can do. The difference between drusen that are growing harmlessly slowly and drusen that are about to collapse into atrophy is often visible on the scan months before you notice any change in your vision.

Home Monitoring Between Appointments

Between office visits, an Amsler grid remains a simple and useful self-check. This is a printed grid of straight lines with a central dot. You look at the dot with one eye at a time, and any new distortion, waviness, or missing areas in the lines can signal a change in the macula that warrants an urgent appointment rather than waiting for your next scheduled one. Your doctor can provide one, or you can find printable versions from reputable eye health organizations. The grid is particularly important for catching the sudden onset of wet AMD, where abnormal blood vessels grow beneath the retina and can cause rapid vision loss if untreated. While drusen themselves are a dry AMD feature, people with large drusen are at risk for converting to the wet form, and catching that conversion early is one of the clearest situations where timely action saves vision.

Dark adaptation testing is another functional marker that may become more common. Some clinics already use devices that measure how quickly your eyes recover sensitivity after a bright flash. Prolonged dark adaptation has been proposed as one of the earliest functional signs that the RPE is struggling, even before drusen are large enough to show on standard imaging. If this kind of testing becomes widely available, it could help identify the people who would benefit most from aggressive supplement use, dietary change, or enrollment in clinical trials of new treatments.